Followers

Monday, December 15, 2008

Antisocial, Invasive Cells Are Basis Of Cancer, Finding Suggests


Photomicrograph of cervical cancer cells in tissue culture. New research finds that cancer cells sidestep the mechanism by which cells normally repel each other. (Credit: iStockphoto/Torsten Wittmann)

Scientists at UCL funded by BBSRC and the Medical Research Council have discovered the mechanism by which cells normally repel each other – a process sidestepped by cancer cells which go on to invade and conquer healthy regions of the body.

The findings suggest an alternative way in which cancer treatments might work in the future, if therapies can be targeted at the process of ‘cell repulsion’ to stop cancer cells from spreading and causing secondary tumours.

Cells typically produce localized protrusions which help them navigate their environment. When two cells meet, they normally retract their protrusions and change their direction of movement, effectively ‘repelling’ one another. This phenomenon, called contact inhibition of locomotion, was first discovered 50 years ago in a UCL laboratory experiment, and its failure was thought to contribute to the malignant invasion of cancer. But it took up to now to witness the process in action and pin down the mechanism.

The latest UCL study led by Dr Roberto Mayor, UCL Cell and Developmental Biology, has captured the phenomenon ‘in vivo’ – in living tissue – and has identified the mechanism by which it works, suggesting possible new targets for future cancer therapies.

Dr Roberto Mayor says: "Contact inhibition of locomotion was first discovered by UCL Professor Michael Abercrombie more than 50 years ago, when he saw fibroblast cells under the microscope confront each other, retract their protrusions and change direction on contact. The failure of cells to repulse each other in this way was thought to play a role in the spread of cancer."

"However, until now the molecular basis of this process and whether it also occurred within the body was unknown. Our study of neural crest cells shows that these cells behave in exactly this way. When two migrating neural crest cells meet, they stop, collapse their protrusions and change direction. However, when a neural crest cell meets another cell type, it fails to behave as expected and instead invades the other tissue, in the same manner as metastatic cancer cells which migrate and go on to cause secondary tumours."

"Inhibition of a type of cell signalling - non-canonical Wnt signalling – is behind this behaviour, cancelling the normal repulsion you would expect between cells. Our discovery offers possible new targets for the future treatment of tumour metastasis – the spreading of cancer cells, one of the mostly deadly aspects of cancer."

Original here


Broccoli Compound Targets Key Enzyme In Late-stage Cancer


Broccoli. An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer. (Credit: iStockphoto/David T Gomez)

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing Dec 3 in the online early edition of the journal Proceedings of the National Academy of Sciences.

The compound, indole-3-carbinol, is already undergoing clinical trials in humans because it was found to stop the growth of breast and prostate cancer cells in mice.

The new findings are the first to explain how indole-3-carbinol (I3C) stops cell growth, and thus provides the basis for designing improved versions of the chemical that would be more effective as a drug and could work against a broader range of breast as well as prostate tumors.

"I think one of the real uses of this compound and its derivatives is combining it with other kinds of therapies, such as tamoxifen for breast cancer and anti-androgens for prostate cancer," said coauthor Gary Firestone, UC Berkeley professor of molecular and cell biology. "Humans have co-evolved with cruciferous vegetables like broccoli and Brussels sprouts, so this natural source has a lot fewer side effects."

"This is a major breakthrough in trying to understand what the specific targets of these natural products are," said coauthor Leonard Bjeldanes, UC Berkeley professor of toxicology. "The field is awash with different results in various cells, but no real identification of a specific molecular target for these substances. The beauty of identifying the target like this is that it suggests further studies that could augment the activity of this type of molecule and really specify uses for specific cancers."

Firestone, Bjeldanes and their colleagues showed that I3C inhibits the enzyme elastase, which at high levels in breast cancer cells heralds a poor prognosis: decreased response to chemotherapy, reduced response to endocrine treatment and reduced survival rates.

Elastase is an enzyme that shortens a cellular chemical, cyclin E, that is involved in controlling the cell cycle. The shortened version of cyclin E accelerates the cell cycle, making cancer cells proliferate faster. Firestone showed that I3C prevents the elastase shortening of cyclin E, thereby arresting development of breast cancer cells.

For more than 15 years, Firestone, Bjeldanes and their colleagues have studied the anti-cancer benefits of vegetables in the cabbage family that are lumped together in the genus Brassica and, because of their cross-shaped flowers, are often referred to as cruciferous vegetables.

Though the anti-cancer benefits have been recognized since the 1970s, the mechanism is only now being discovered, in part through the work of Firestone, Bjeldanes and their UC Berkeley colleagues.

"We have connected the dots on one extremely important pathway" by which indole-3-carbinol works, Firestone said.

In previous work, they found that indole-3-carbinol interferes with more than cell proliferation. It also disrupts the migration and alters adhesion properties of cancer cells, as well as counteracts the survival ability of cancer cells, all of which are implicated in cancer cell growth. To have such broad downstream effects, I3C must act at the beginning of a major cellular pathway, Firestone said. The newly reported research pins this activity to elastase and its effect on cyclin E.

Bjeldanes noted that I3C is available as a supplement and is a preferred preventative treatment for recurrent respiratory papillomatosis, a condition involving non-malignant tumors of the larynx. Improved versions of the chemical could thus help treat cancers other than those of the breast and prostate.

Graduate student Ida Aronchik and recent Ph.D. recipient Hanh H. Nguyen, along with colleagues in the Firestone and Bjeldanes labs, have already chemically modified I3C and boosted its activity in cell culture by at least a factor of 100. The lab teams currently are probing the elastase structure and how I3C interacts with it to identify the best parts of the I3C molecule to modify.

I3C is only one of many plant-derived chemicals, called phytochemicals, that Firestone is investigating in his laboratory as potential anti-cancer agents. Among them is the anti-malarial drug artemisinin. Last month, the Journal of Biological Chemistry accepted a paper by Firestone and his colleagues showing that artemisinin blocks prostate cancer cell growth by interfering with the same intracellular pathway as does I3C. This pathway involves the transcription factor SP1, which latches onto other genes to boost their activity.

"SP1 could be a generalized target of phytochemicals," Firestone said. "Phytochemicals work because they interact with and inhibit enzymes that control a host of cellular processes, including migration and adhesion."

The research is supported by the National Cancer Institute. Other coauthors of the paper are Gloria A. Brar, currently a graduate student at the Massachusetts Institute of Technology, and former UC Berkeley undergraduate David H. H. Nguyen, now a graduate student at New York University.

Original here


Teens Favor Painkillers, Alcohol and Marijuana Over Stimulants

Many teens are still abusing prescription painkillers, even as the use of stimulant drugs declined, according to an annual study of teen drug and alcohol use released today.

abused drugsThe 2008 Monitoring the Future Survey, conducted by scientists at the University of Michigan and sponsored by the National Institute on Drug Abuse, which is part of the NIH, surveyed 8th, 10th and 12th graders about their habits regarding drugs and alcohol. This is the 34th year for the study.

Earlier this year, the WSJ reported that an increasing number of young people, dubbed “Generation Rx” by some drug experts, are abusing prescription drugs, especially narcotics such as OxyContin, Vicodin and Percoset. Sure enough, the 2008 MTF data show the rates of abuse of these prescription narcotics remain high, with little change in the past six years. (Click on graphic to enlarge chart of most abused drugs.)

Nearly 10% of high school seniors reported using Vicodin for non-medical purposes in the year before taking the survey, while 4.7% reported abusing OxyContin. Both drugs are opioid painkillers.

“It’s a very serious problem,” Nora Volkow, director of the National Institute on Drug Abuse, told the Health Blog. “There’s a misconception that these drugs are safer than illicit substances because they are prescribed by doctors.”

Meanwhile, the levels of abuse of over-the-counter cough and cold medications varied by age. Their abuse remained fairly high among 10th graders, since first being tracked in 2006, but fell among 8th and 12th graders.

There was some good news in the survey: The use of some stimulants—amphetamines, methamphetamine, crystal methamphetamine, cocaine and crack—continued a gradual decline. In addition, cigarette smoking among teens is at its lowest rates since the survey started in 1975.

Teen alcohol use has declined since the mid-1990s, though the levels are still pretty high. The 2008 survey showed that the number of 8th and 12th graders who reported that they drank alcohol one or more times in the past year remained fairly steady at about 32% and about 66% respectively. The number of 10th graders who reported alcohol use in the past year fell 3.8% to 52.5%.

The study showed that marijuana use among teens, which has consistently declined since the mid-1990s, appears to have leveled off, with 10.9% of 8th graders, 23.9% of 10th graders and 32.4% of 12th graders reporting using it in the past year. Teen use of several other illicit drugs, including LSD, ecstasy and heroin remained steady.

Original here